Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

1628530-47-1Cabozantinib 6 Hydroxy Impurity

● Auf Lager

Katalog-Nr.::	VE0024708
CAS-Nr.::	1628530-47-1
Summenformel::	C27H22FN3O5
Molare Masse::	487.48 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 1628530-47-1

Parent drug

Cabozantinib

IUPAC-Name

N-(4-fluorophenyl)-N-(4-((6-hydroxy-7-methoxyquinolin-4-yl)oxy)phenyl)cyclopropane-1, 1-dicarboxamide

Pharmakopöe-Synonyme

N/A

Other Synonyms

1, 1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N?-[4-[(6-hydroxy-7-methoxy-4-quinolinyl)oxy]phenyl]

SMILES

OC1=C(OC)C=C(N=CC=C2OC3=CC=C(NC(C4(CC4)C(NC5=CC=C(F)C=C5)=O)=O)C=C3)C2=C1

InChI

InChI=1S/C27H22FN3O5/c1-35-24-15-21-20(14-22(24)32)23(10-13-29-21)36-19-8-6-18(7-9-19)31-26(34)27(11-12-27)25(33)30-17-4-2-16(28)3-5-17/h2-10, 13-15, 32H, 11-12H2, 1H3, (H, 30, 33)(H, 31, 34)

Beschreibung

Cabozantinib 6 Hydroxy Impurity is a well-characterized reference material that meets stringent regulatory standards set by USP | EMA | JP | and BP. It plays a key role in Abbreviated New Drug Applications (ANDA) | New Drug Applications (NDA) | and the commercial production of Cabozantinib.